We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Precision Assignment of Intervention Messages to Promote Physical Activity - Precision AIM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04972279
Recruitment Status : Active, not recruiting
First Posted : July 22, 2021
Last Update Posted : August 10, 2022
Sponsor:
Information provided by (Responsible Party):
David E Conroy, Penn State University

Brief Summary:
Our goal is to develop personalized decision rules for selecting the frequency, timing, and content of messages to promote physical activity. The objective of this project is to evaluate the acceptability and feasibility of two strategies for calibrating decision rules used to send those messages. Participants will wear an activity monitor for the collection of PA data and be randomly assigned to one of two adaptive intervention strategies. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions. Our hypothesis is that more intensive intervention strategies will offer a better user experience because the resulting treatments will be experienced as more personalized.

Condition or disease Intervention/treatment Phase
Cardiovascular Risk Factor Behavioral: Digital message (text + image) Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Prevention
Official Title: Phase 1 Clinical Trial to Develop a Personalized Adaptive Text Message Intervention Using Control Systems Engineering Tools to Increase Physical Activity in Early Adulthood
Actual Study Start Date : January 2, 2022
Estimated Primary Completion Date : December 15, 2022
Estimated Study Completion Date : December 15, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Health Checkup

Arm Intervention/treatment
Experimental: Aggressive adaptation strategy
Participants receive up to 6 messages/day to support achievement of their behavior change goal. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages with coordinating images are selected from three content domains: Move More, Sit Less, and Inspirational Quotes Unrelated to Movement within the first month. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions.
Behavioral: Digital message (text + image)
Messages can be up to 256 characters of text with an image. "Move more" and "sit less" messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity).

Experimental: Moderate adaptation strategy
Participants receive up to 3 messages/day to support achievement of their behavior change goal. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages with coordinating images are selected randomly from three content domains: Move More, Sit Less, and Inspirational Quotes Unrelated to Movement within the first month. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions.
Behavioral: Digital message (text + image)
Messages can be up to 256 characters of text with an image. "Move more" and "sit less" messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity).




Primary Outcome Measures :
  1. Acceptability of messaging at 6 months [ Time Frame: 6 months ]
    Self-reported preference for more, no change or fewer messages/day based on participant exit interviews coded by two blinded research assistants


Secondary Outcome Measures :
  1. Change in total physical activity volume from run-in period [ Time Frame: Baseline and 6 months ]
    Actigraph-assessed total activity counts during a 1-week monitoring period at baseline versus end of study

  2. Change in moderate-to-vigorous physical activity duration from run-in period (baseline) to 6 months(baseline) to 6 months [ Time Frame: Baseline and 6 months ]
    Actigraph-assessed min/week of moderate (or higher) physical activity duration during a 1 week monitoring period at baseline versus end of study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 29 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participants capable of reading, speaking and understanding English and of giving informed consent.
  • Participants between the ages of 18-29 years.
  • Participants must be free of visual impairment that would interfere with the receipt of text messages on their phone.
  • Participants must be willing to wear a Fitbit Versa 3 almost continually (23.5 hours/day) for a 6- month period of time.
  • Participants must own an iPhone or Android smartphone that they would be willing to download the custom Precision AIM and Fitbit app onto and sync with a Fitbit Versa 3.
  • Participants interested in setting goals to increase their physical activity levels over the 6-month study.

Exclusion Criteria:

  • Participants engaging in 150 or more minutes of moderate- or greater intensity PA /week as assessed by a research grade accelerometer.
  • Participants engaged in organized programs with mandated physical activity (e.g., varsity sports, ROTC).
  • Participants with contraindications to normal physical activity on the Physical Activity Readiness Questionnaire.
  • Participants who require an assistive device for mobility or have any other condition that may limit or prevent participation in moderate-intensity physical activity.
  • Participants who are pregnant or planning to become pregnant within the next 6 months.
  • Participants with a prior diagnosis of cancer, cardiovascular disease, diabetes or metabolic syndrome.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04972279


Locations
Layout table for location information
United States, Pennsylvania
The Pennsylvania State University
University Park, Pennsylvania, United States, 16802
Sponsors and Collaborators
Penn State University
Investigators
Layout table for investigator information
Principal Investigator: David E Conroy, PhD The Pennsylvania State University
Layout table for additonal information
Responsible Party: David E Conroy, Professor, Penn State University
ClinicalTrials.gov Identifier: NCT04972279    
Other Study ID Numbers: STUDY00016346
First Posted: July 22, 2021    Key Record Dates
Last Update Posted: August 10, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No